ABSTRACT
This study examined how race/ethnicity, sex/gender, and sexual orientation intersect to socially pattern depression among US adults. We used repeated, cross-sectional data from the 2015-2020 National Survey on Drug Use and Health (NSDUH; n=234,772) to conduct design-weighted multilevel analysis of individual heterogeneity and discriminatory accuracy (MAIHDA) for two outcomes: past-year and lifetime major depressive episode (MDE). With 42 intersectional groups constructed from seven race/ethnicity, two sex/gender, and three sexual orientation categories, we estimated group-specific prevalence and excess/reduced prevalence attributable to intersectional effects (i.e., two-way or higher interactions between identity variables). Models revealed heterogeneity between intersectional groups, with prevalence estimates ranging from 3.4–31.4% (past-year) and 6.7–47.4% (lifetime). Model main effects indicated that people who were Multiracial, White, women, gay/lesbian, or bisexual had greater odds of MDE. Additive effects of race/ethnicity, sex/gender, and sexual orientation explained most between-group variance; however, approximately 3% (past-year) and 12% (lifetime) were attributable to intersectional effects, with some groups experiencing excess/reduced prevalence. For both outcomes, sexual orientation main effects (42.9–54.0%) explained a greater proportion of between-group variance relative to race/ethnicity (10.0–17.1%) and sex/gender (7.5–7.9%). Notably, we extend MAIHDA to calculate nationally representative estimates to open future opportunities to quantify intersectionality with complex sample survey data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Institute of Mental Health [T32MH019960 to FHM], the National Institute on Minority Health and Health Disparities [F32MD017452 to ALB], and the National Institute on Drug Abuse [T32DA015035 to JP].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data are publicly available from the Substance Abuse and Mental Health Services Administration: https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflicts of interest: The authors have no conflicts of interest to report.
Funding: This work was supported by the National Institute of Mental Health [T32MH019960 to FHM], the National Institute on Minority Health and Health Disparities [F32MD017452 to ALB], and the National Institute on Drug Abuse [T32DA015035 to JP].
Data availability: All data and code are publicly available through the corresponding author’s GitHub repository.
Data Availability
All data and R code are available online at: https://github.com/fhmcguire/NSDUH_intersectional_depression
https://github.com/fhmcguire/NSDUH_intersectional_depression
